Corrigendum to “Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany”

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Breast
Päätekijät: Schneeweiss, Andreas, Ettl, Johannes, Lüftner, Diana, Beckmann, Matthias W., Belleville, Erik, Fasching, Peter A., Fehm, Tanja N., Geberth, Matthias, Häberle, Lothar, Hadji, Peyman, Hartkopf, Andreas D., Hielscher, Carsten, Huober, Jens, Ruckhäberle, Eugen, Janni, Wolfgang, Kolberg, Hans Christian, Kurbacher, Christian M., Klein, Evelyn, Lux, Michael P., Müller, Volkmar, Nabieva, Naiba, Overkamp, Friedrich, Tesch, Hans, Laakmann, Elena, Taran, Florin-Andrei, Seitz, Julia, Thomssen, Christoph, Untch, Michael, Wimberger, Pauline, Wuerstlein, Rachel, Volz, Bernhard, Wallwiener, Diethelm, Wallwiener, Markus, Brucker, Sara Y.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier 2021
Aiheet:
Corrigendum
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7878444/
https://ncbi.nlm.nih.gov/pubmed/33413981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.breast.2020.12.007
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia